Royce & Associates LP Acquires New Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Royce & Associates LP initiated a new position in Centessa Pharmaceuticals (NASDAQ:CNTA), purchasing 247,387 shares valued at about $6.0 million, representing roughly 0.18% of the company.
• Institutional investors own a large majority of the stock (about 82.01%), while insiders have reduced holdings—selling 49,961 shares worth approximately $1.30 million in the last quarter, leaving insiders with 7.09% ownership.
• Wall Street sentiment is broadly positive with a MarketBeat consensus rating of Buy and a consensus target price of $38.64 (compared with a recent price near $26.70), indicating potential upside per analysts.

Royce & Associates LP bought a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 247,387 shares of the company's stock, valued at approximately $5,999,000. Royce & Associates LP owned approximately 0.18% of Centessa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of CNTA. Campbell & CO Investment Adviser LLC acquired a new position in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $218,000. DNB Asset Management AS bought a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $218,000. China Universal Asset Management Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company's stock worth $252,000 after purchasing an additional 870 shares during the period. GSA Capital Partners LLP bought a new position in Centessa Pharmaceuticals during the 3rd quarter worth about $455,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Centessa Pharmaceuticals by 3,028.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company's stock valued at $460,000 after purchasing an additional 33,854 shares during the period. Institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Up 1.9%

Centessa Pharmaceuticals stock opened at $26.70 on Thursday. The company's 50-day moving average price is $24.42 and its two-hundred day moving average price is $23.82. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The stock has a market cap of $3.90 billion, a P/E ratio of -14.59 and a beta of 1.55. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $30.58.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CNTA. Piper Sandler reiterated an "overweight" rating on shares of Centessa Pharmaceuticals in a report on Friday, January 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Oppenheimer lifted their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an "outperform" rating in a research note on Wednesday, December 10th. Wolfe Research assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They issued an "outperform" rating and a $40.00 target price on the stock. Finally, Guggenheim raised their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a "buy" rating in a research note on Tuesday, November 18th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $38.64.

Insider Buying and Selling

In related news, insider Mario Alberto Accardi sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the sale, the insider directly owned 178,801 shares of the company's stock, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of the company's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the transaction, the insider directly owned 57,645 shares in the company, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 49,961 shares of company stock worth $1,304,878. 7.09% of the stock is owned by corporate insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.